Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)

Infliximab for the treatment of psoriasis in the U.K.: 9 years’ experience of infusion reactions at a single centre

(2012) J.S. Wee et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring

(2012) Raja K. Sivamani et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Anti-infliximab antibodies in inflammatory bowel disease

(2012) Lennard Y.W. Lee et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

(2011) C. Steenholdt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

(2009) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS